# Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

> **NCT00558272** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 139 (actual)

## Conditions studied

- Breast Cancer
- Prostate Cancer
- Bone Neoplasms

## Interventions

- **DRUG:** AZD0530
- **DRUG:** Zoledronic Acid

## Key facts

- **NCT ID:** NCT00558272
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-01
- **Final completion:** 2012-08
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2013-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558272, "Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00558272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*